POSSÍVEL UTILIZAÇÃO DE CANABINOIDES NA DOENÇA DE ALZHEIMER: UMA REVISÃO

Vagner Fagnani Linartevichi; Rafael de Morais Cury; Francisney Pinto Nascimento

doi:10.35984/fjh.v3i2.365

Vagner Fagnani Linartevichi Programa de Pós-Graduação em Biociências - Universidade Federal da Integração Latino-Americana https://orcid.org/0000-0002-2624-7744
Rafael de Morais Cury Programa de Pós-Graduação em Biociências - Universidade Federal da Integração Latino-Americana https://orcid.org/0000-0001-6745-5390
Francisney Pinto Nascimento Docente do Programa de Pós-Graduação em Biociências - Universidade Federal da Integração Latino-Americana

DOI: https://doi.org/10.35984/fjh.v3i2.365

Palavras-chave: Canabinoides, Endocanabinoides, Neurodegeneração

Resumo

O presente estudo teve por objetivo realizar uma revisão exploratória da literatura sobre o uso de canabinoides para o tratamento da DA no intuito de discutir a utilização medicinal destas substâncias para possíveis tratamentos futuros. Revisão dissertativa da literatura no qual os artigos foram buscados por meio de duas variáveis sendo elas a doença (Alzheimer’s Disease, Alzheimer Dementia) e a intervenção (Cannabi, Marihuana, Cannabis sativa, sativa, indicas, Cannabis). Os resultados mostrados na literatura sugerem que os fitocanabinoides podem ser uma ferramenta útil na DA, principalmente pelo fato de estudos isolados mostrarem a supressão dos fatores relacionados com a neurobiologia da doença. Aparentemente a associação de CBD e THC parece ser mais promissora do que seu uso isoladamente. Neste contexto, o uso clínico de canabinoides deve ser considerado como uma possível ferramenta farmacológica no tratamento de diversas doenças incluindo a DA. Para tanto, mais estudos clínicos devem ser estimulados.

Referências

AHMED A, ELSEN G, COLBERS A, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology, v. 232, p. 2587-2595, 2015. http://doi.org/10.1007/ s00213-015-3889-y

ESPOSITO G, SCUDERI C, SAVANI C, STEARDO L, DE FILIPPIS D, COTTONE P, et al. Cannabidiol in vivo blunts β-amy¬loid induced neuroinflammation by suppressing IL-1β and iNOS expression. British Journal of Pharmacology, v. 151, n. 8, p. 1272-1279, 2007, http://doi.org/10.1038/sj.bjp.0707337

FELLERMEIER M, EISENREICH W, BACHER A, ZENK MH, Biosynthesis of cannabinoids. Eur J Biochem, v. 268, p. 1596-1604, 2001, http://doi.org/10.1046/j.1432-1033.2001.02030.x

GIUSEPPE E, CATERINA S, MARTA V, GIUSEPPINA IT, VALENTI¬NA L, DANIELE DF, et al. Cannabidiol reduces Aβ-in¬duced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLOS ONE, v.6, n. 12, p. 28668, 2011, http://doi.org/10.1371/journal.pone.0028668

HA SY. Perception Survey of the Use of Medical Mari-huana Targeting Cancer-Patients and each of their Pro¬tectors. 2018, Korea:Hansung Univ. [Dissertation]

HAN DY, PARK NE, KIM SH, JEONG DG. The Effect of Oral Administration of Herbal Medicines on Memo¬ry in Alzheimer's Disease Animal Models: A Review of Animal Study Reports Published in Korea. JPPKM, v. 28, n. 4, p. 359-371, 2017, http://doi.org/10.3831/KPI.2019.22.030

INGLET S, WINTER B, YOST SE, ENTRINGER S, LIAN A, BIKSACKY M, PITT RD, MORTENSEN W. Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. Annals of Pharmacotherapy, v. 54, n. 11, p. 1109-1143, 2020. http://doi.org/10.1177/1060028020930189.

IUVONE T, ESPOSITO G, DE FILIPPIS D, SCUDERI C, STEARDO L. Cannabidiol: A promising drug for neurodegenerative disorders? CNS Neuroscience & Therapeutics, v.15, p. 65-75, 2009, http://doi.org/10.1111/j.1755-5949.2008.00065.x

KOPPEL BS, BRUST JCM, FIFE T, BRONSTEIN J, YOUSSOF S, GRONSETH G, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders, Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, v. 82, p. 1556-1563, 2014, http://doi.org/10.1212/WNL.0000000000000363

LIGRESTI A, DE PETROCELLIS L, DI MARZO V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. Physiological Reviews, v. 96, p. 1593-1659, 2016, http://doi.org/10.1152/physrev.00002.2016

LINARTEVICHI, VF.; FROZA, MG.; CURY, RM.; NASCIMENTO, FP. Potencial uso da psilocibina no tratamento da depressão: uma revisão. Brazilian Journal of Development, v. 7, n. 3, p. 32270-32288, 2021, https://doi.org/10.34117/bjdv7n3-783

MARESE, A.; FICAGNA, E.; PARIZOTTO, R.; LINARTEVICHI, V. Principais mecanismos que correlacionam a microbiota intestinal com a patogênese da depressão. Fag Journal of Health, v. 1, n. 3, p. 232-239, 20 out. 2019. https://doi.org/10.35984/fjh.v1i2.40

MAROON J., BOST J. Review of the neurological benefits of phytocannabinoids. Surgical Neurology International, v. 9, p. 91-104, 2018. https://doi.org/10.4103/sni_45_18

MECHA M, TORRAO AS, MESTRE L, CARRILLO SALINAS FJ, MECHOULAM R, GUAZA C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Disease, v. 3, p. 331, 2012, http://doi.org/10.1038/cddis.2012.71

NESTLER EJ, BARROT M, DILEONE RJ, EISCH AJ, GOLD SJ, MONTEGGIA LM. Neurobiology of depression. Neuron, v. 34, p. 13-25, 2002, http://doi.org/10.1016/s0896-6273(02)00653-0

OIDE T, KINOSHITA T, ARIMA K. Regression stage se¬nile plaques in the natural course of alzheimer's dis¬ease. Neuropathology and Applied Neurobiology, v. 32, n. 5, p. 539-556, 2006, http://doi.org/10.1111/j.1365-2990.2006.00767.x

PARK MS, KIM YM. Study on Syndrome Differentiation of Dementia. JPPKM, v. 28, n. 3, p. 251-262, 2014, http://doi.org/10.15188/kjopp.2014.06.28.3.251

PATRICIA R, JOSEPH S. Medical Marijuana and pain man-agement. Peer-reviewed excellence in life care plan-ning, v. 19, n. 3, p. 20-25, 2019, http://doi.org/10.1016/j.disamonth.2016.05.014

PERTWEE RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9 tetrahydrocannabinol, cannabidiol and Δ9 tetrahydrocannabivarin. British Journal of Pharmacology, v. 153, p. 199-215, 2008. http://doi.org/10.1038/sj.bjp.0707442

RAMIREZ BG, BLAZQUEZ C, GOMEZ DEL PULGAR T, GUZMAN M, DE CEBALLOS ML. Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. The Journal of Neuroscience, v. 25, p. 1904-1913, 2005. https://doi.org/10.1523/jneurosci.4540-04.2005

RUTHIRAKUHAN M, LANCTÔT KL, VIEIRA D, HERRMANN N. Natural and synthetic cannabinoids for agitation and aggression in Alzheimer’s disease: a meta-analysis. The Journal of Clinical Psychiatry, v. 80, n. 18, p. 12617, 2019. http://doi.org/10.4088/JCP.18r12617

SAGREDO O, RAMOS JA, DECIO A, MECHOULAM R, FERNANDEZ RUIZ J. Cannabidiol reduced the striatal atrophy caused 3 nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. European Journal of Neuroscience, v.26, p. 843-851, 2007. http://doi.org/10.1111/j.1460-9568.2007.05717.x.

SALAZAR M, CARRACEDO A, SALANUEVA IJ, HERNANDEZ TIEDRA S, EGIA A, LORENTE M, et al. TRB3 links ER stress to autophagy in cannabinoid anti tumoral action. Autophagy, v. 5, p. 1048-1049, 2009, http://doi.org/10.4161/auto.5.7.9508

SCHURMAN LD, LICHTMAN AH. Endocannabinoids: A promising impact for traumatic brain injury. Frontiers in Pharmacology, v. 8, p. 69, 2017, http://doi.org/doi.org/10.3389/fphar.2017.00069

SHELEF A, BARAK Y, BERGER U, et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. Journal of Alzheimer's Disease, v. 51, p. 15-19, 2016. http://doi.org/10.3233/JAD-150915

SVÍŽENSKÁ, I., DUBOVÝ, P., & ŠULCOVÁ, A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures: a short review. Pharmacology Biochemistry, and Behaviour, v. 90, p. 501–511, 2009. http://doi.org/10.1016/j.pbb.2008.05.010

URIBE MARIÑO A, FRANCISCO A, CASTIBLANCO URBINA MA, TWARDOWSCHY A, SALGADO ROHNER CJ, CRIPPA, J, et al. Anti Aversive Effects of Cannabidiol on Innate Fear Induced Behaviors Evoked by an Ethological Model of Panic Attacks Based on a Prey vs the Wild Snake Epicrates cenchria crassus Confrontation Paradigm. Neuropsychopharmacology, v. 37, p. 412-421, 2012, http://doi.org/10.1038/npp.2011.188

VALDEOLIVAS S, SATTA V, PERTWEE RG, FERNANDEZ RUIZ J, SAGREDO O. Sativex like combination of phytocannabinoids is neuroprotective in malonate lesioned rats, an inflammatory model of Huntington’s disease: Role of CB1 and CB2 receptors. ACS Chem Neurosci, v. 3, p. 400-406, 2012, http://doi.org/10.1021/cn200114w

VELENOVSKÁ M, FISAR Z. Effect of cannabinoids on platelet serotonin uptake. Addiction Biology, v.12, p. 158-166, 2007, http://doi.org/10.1111/j.1369-1600.2007.00065.x

WADA. AMA.org. The world anti doping code international standard prohibited list, January 2018. Available from: https://www.wada ama.org/sites/default/ files/prohibited_list_2018_en.pdf. [Last accessed on 2021 Jan 12].

WALTHER S, MAHLBERG R, EICHMANN U, KUNZ D. Delta 9 tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology, v. 185, p. 524-528, 2006, http://doi.org/10.1007/s00213-006-0343-1